Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. Venus Medtech (Hangzhou) Inc.
  6. News
  7. Summary
    2500   CNE100003PJ8

VENUS MEDTECH (HANGZHOU) INC.

(2500)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Venus Medtech Inc. Appoints Martin B. Leon as the Global Principal Investigator of RDN Innovative System

07/27/2021 | 04:34am EDT

The board of Venus Medtech (Hangzhou) Inc. announced that Professor Martin B. Leon has been appointed as the global Principal Investigator ("PI") for the new generation of renal artery denervation ("RDN") innovative system developed by Renaly Ltd. ("Renaly"), controlling subsidiary. Meanwhile, he also serves as the director of Columbia Interventional Cardiovascular Care, director of the Cardiac Catheterization Laboratory, and the director of the Executive Board of the Columbia Structural Heart & Valve Center. In addition, he is also the founder and chairman of the global Transcatheter Cardiovascular Therapeutics ("TCT") conference. In the field of RDN, Professor Martin and his team have been serving as the PI for clinical trials for several innovative systems including Medtronic's Symplicity SpyralTM Renal Denervation System and ReCor Medical's ParadiseTM Ultrasonic Denervation System, both of which were awarded Breakthrough Device Designation by the U.S Food and Drug Administration in 2020. The new generation of RDN innovative system is developed by Renaly. Its exclusive Dual-Mode Ultrasound Technology (DMUT) Platform can realize non-contact continuous ablation treatment with real-time monitoring function, which significantly reduces the occurrence of various problems such as insufficient nerve ablation or vascular damage caused by uncontrollable ablation while achieving accurate and efficient ablation, in order to shift the treatment paradigm to more predictable outcomes and simplify the operation procedure flow to ultimately improve the safety and efficacy of ablation procedures.


ę S&P Capital IQ 2021
All news about VENUS MEDTECH (HANGZHOU) INC.
08/31Venus Medtech Hangzhou Inc. Reports Earnings Results for the Half Year Ended June 30, 2..
CI
08/31Venus Medtech Inc. Announces Unaudited Consolidated Earnings Results for the Six Months..
CI
08/16VENUS MEDTECH HANGZHOU : Unveils Plan to Buy Medical Device Research and Development Busin..
MT
07/27VENUS MEDTECH HANGZHOU : Appoints Professor Martin B. Leon as Global Principal Investigato..
AQ
07/27VENUS MEDTECH HANGZHOU : Appoints Professor Martin B. Leon as Global Principal Investigato..
PR
07/27Venus Medtech Inc. Appoints Martin B. Leon as the Global Principal Investigator of RDN ..
CI
07/26VENUS MEDTECH HANGZHOU : Voluntary announcement unaudited operating statistics for the per..
PU
07/26Venus Medtech Inc. Announces Unaudited Group Revenue Results for the Six Months Ended J..
CI
06/30Venus Medtech Inc. Announces Formation of Joint Venture Company with Healium Medical Lt..
CI
05/06VENUS MEDTECH HANGZHOU : Voluntary announcement latest investment project
PU
More news
Financials
Sales 2021 554 M 85,8 M 85,8 M
Net income 2021 -152 M -23,5 M -23,5 M
Net cash 2021 2 429 M 376 M 376 M
P/E ratio 2021 -113x
Yield 2021 -
Capitalization 17 067 M 2 192 M 2 642 M
EV / Sales 2021 26,4x
EV / Sales 2022 14,8x
Nbr of Employees 675
Free-Float 76,4%
Chart VENUS MEDTECH (HANGZHOU) INC.
Duration : Period :
Venus Medtech (Hangzhou) Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VENUS MEDTECH (HANGZHOU) INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 38,70 CNY
Average target price 60,30 CNY
Spread / Average Target 55,8%
EPS Revisions
Managers and Directors
Zhen Jun Zi Executive Director & General Manager
Haiyue Ma Chief Financial Officer & Joint Secretary
Min Zeng Chairman
Yan Xiao Chairman-Supervisory Board
Hou-Sen Lim Chief Operating Officer, Executive Director & CTO
Sector and Competitors